Ocular Therapeutix™ Appoints George Migausky as Interim Chief Financial Officer
April 06 2017 - 8:00AM
Business Wire
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical
company focused on the development, manufacturing and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced the appointment of George
Migausky as interim Chief Financial Officer. Mr. Migausky brings
more than 30 years of experience in senior financial management to
Ocular Therapeutix. In his new role, he will have Ocular’s
financial and administrative groups reporting to him while the
Company continues to evaluate candidates for the permanent CFO
role. Mr. Migausky replaces Brad Smith who recently relinquished
his role as CFO at the Company.
“George is a highly regarded financial professional, offering
extensive expertise at high-growth private and public life sciences
and technology,” said Amar Sawhney, Ph.D., President, Chief
Executive Officer and Chairman of Ocular. “We believe his insights
will be invaluable as we continue to undertake
pre-commercialization activities for DEXTENZA™ in advance of the
July 19th PDUFA date and as we make further substantial progress
across our additional drug product development programs.”
Dr. Sawhney added, “On behalf of everyone at Ocular Therapeutix,
I would also like to thank Brad for his contributions at Ocular. He
has been an essential part of Ocular’s success and growth over the
past three years, and we wish him the best of luck in his future
endeavors.”
Most recently, Mr. Migausky was Executive Vice President and
Chief Financial Officer of Dyax Corp., through its $6+ billion
merger with Shire plc in 2016. Previously, Mr. Migausky served as
the CFO of Wellstat Management Company, a firm responsible for
strategy and operations of an affiliated group of five life science
companies. Prior to this, he held CFO positions at several public
and private companies, including IGEN International, Inc., where he
played a pivotal role in the company’s IPO and subsequent $1.5
billion merger with F. Hoffman La Roche. Mr. Migausky is on the
Boards of Dimension Therapeutics, Inc. and Hyperion Catalysis
International, and is a trustee at the Massachusetts Ear and Eye
Infirmary. He received his M.B.A. degree from Babson College and
B.S. degree from Boston College.
“I am thrilled that Amar and his team have asked me to step into
this key role at Ocular,” said Mr. Migausky. “I look forward to
working closely with management and contributing to the Company’s
advancement as it plans for a potential product launch and
commercialization.”
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused
on the development, manufacturing and commercialization of
innovative therapies for diseases and conditions of the eye using
its proprietary hydrogel platform technology. Ocular Therapeutix’s
lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4mg for
intracanalicular use has completed Phase 3 clinical development for
the treatment of ocular pain and inflammation occurring after
ophthalmic surgery. The FDA has accepted the Company’s NDA
resubmission for DEXTENZA for the treatment of ocular pain
occurring after ophthalmic surgery and has established a target
PDUFA date of July 19, 2017. Ocular Therapeutix is also pursuing
additional indications for DEXTENZA. OTX-TP (travoprost insert) is
in Phase 3 clinical development for glaucoma and ocular
hypertension. Ocular Therapeutix is also evaluating injectable drug
delivery depots for back-of-the-eye diseases. Ocular Therapeutix's
first product, ReSure® Sealant, is FDA-approved to seal corneal
incisions following cataract surgery.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for the Company including the development and
regulatory status of the Company’s product candidates, such as the
Company’s expectations and plans regarding regulatory submissions
for and the timing and conduct of clinical trials of DEXTENZA™ for
post-surgical ocular inflammation and pain, including our
expectations regarding the NDA filed with the FDA, DEXTENZA for the
treatment of allergic conjunctivitis, DEXTENZA for dry eye disease
and OTX-TP for the treatment of glaucoma and ocular hypertension,
the potential utility of any of the Company’s product candidates,
potential commercialization of the Company’s product candidates,
the sufficiency of the Company’s cash resources and other
statements containing the words "anticipate," "believe,"
"estimate," "expect," "intend", "goal," "may", "might," "plan,"
"predict," "project," "target," "potential," "will," "would,"
"could," "should," "continue," and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors. Such forward-looking
statements involve substantial risks and uncertainties that could
cause the Company’s clinical development programs, future results,
performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such risks
and uncertainties include, among others, those related to the
timing and costs involved in commercializing ReSure® Sealant or any
product candidate that receives regulatory approval, the initiation
and conduct of clinical trials, availability of data from clinical
trials and expectations for regulatory submissions and approvals,
the Company’s scientific approach and general development progress,
the availability or commercial potential of the Company’s product
candidates, the sufficiency of cash resources and need for
additional financing or other actions and other factors discussed
in the “Risk Factors” section contained in the Company’s quarterly
and annual reports on file with the Securities and Exchange
Commission. In addition, the forward-looking statements included in
this press release represent the Company’s views as of the date of
this release. The Company anticipates that subsequent events and
developments will cause the Company’s views to change. However,
while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing the Company’s views as of
any date subsequent to the date of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170406005561/en/
InvestorsBurns McClellan on behalf of Ocular
TherapeutixSteve Klass,
212-213-0006sklass@burnsmc.comorMediaMedical DynamicsSandra
Correa, 646-599-8637Media and Business Group
Directorscorrea@rxmedyn.comorOcular Therapeutix, Inc.Scott
CorningVice President of Marketing and Commercial
Operationsscorning@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Sep 2023 to Sep 2024